Mid-size pharma operates multi-program portfolios with the regulatory expectations of Big Pharma and the operational headroom of neither. PrismCDM is the regulated operating substrate that delivers portfolio-level Trial Intelligence, execution, evidence, and submission readiness without the platform-engineering investment. Every new program should extend the operating model, not create a new one.
Mid-size pharma carries Big Pharma regulatory expectations on infrastructure that was sized for a single therapeutic area, and on a leadership team that does not have the headroom for a dedicated platform engineering function.
PrismCDM is the operating system Big Pharma builds in-house, available without the build. One substrate across every program, every CRO partnership, every therapeutic area, with portfolio-level readiness by default.
Standardize the operating model once. Scale it across every therapeutic area, program, and CRO partnership. PrismCDM is the regulated operating system Big Pharma builds in-house, available without the platform-engineering investment.
PTII™ composite and sub-indices on every protocol across every program. Leadership sees one portfolio instead of multiple disconnected programs. Amendment risk is visible across the portfolio before the amendment.
The same Trial Intelligence drives the execution workspace, the evidence platform, and the submission readiness scorecard. Programs do not get re-interpreted at the handoff between intelligence and operations.
Internal teams and CRO partners operate on the same regulated substrate while remaining independently scoped. CROs interoperate without per-engagement stack variation.
Continuous evidence accumulation across every program. Inspection Evidence Packages generated on demand, with complete four-anchor provenance.
Every value carries an evidence classification, every artifact carries integrity anchors, every conclusion is traceable. AI is adopted on a regulated substrate from the start, not retrofitted into one. AI you can put in front of a regulator.
Mid-size pharma grows through additional programs, expanded CRO partnerships, and acquisitions. PrismCDM is built so that each of those does not require a new operating environment.
As programs are added, partnerships expand, or acquisitions occur, the operating model remains consistent. New studies inherit the same Trial Intelligence, execution, evidence, and provenance architecture instead of introducing another operating environment.
Three reasons mid-size pharma leadership adopt PrismCDM. The reasons their leadership teams remember after the room clears.
One operating model across every study. Every new program extends the operating model, not replaces it.
Internal teams and CROs operate on the same substrate. Stack variation across partnerships goes away.
Evidence accumulates continuously throughout execution. Submission readiness is the outcome of operating well, not a separate sprint.
